Date
26 September 2023
Scope for generics companies to go further in LMICs
The Pharma Letter reports on the launch of the company profiles report on generic medicine manufacturers, noting that this is the first report from the Foundation's Generic & Biosimilar Medicines Programme, and indeed the first time that these types of companies have been assessed in-depth on their efforts to expand access to medicine.
Direct links
The article acknowledges the report's findings that despite efforts from some of these companies, essential medicines they produce are still out of reach for people living in low- and middle-income countries (LMICs).
The Foundation's CEO, Jayasree Iyer is quoted: "Companies must engage with the unmet medical need globally - for example, by working with local manufacturers to improve supply, by taking steps to safeguard quality, by making their essential products available in more countries and by addressing affordability for the poorest patients."
Read the Foundation's report on generic and biosimilar medicine manufacturers.